CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended		113 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
OPERATING ACTIVITIES
Net loss	$ (4,114)	$ (4,053)	$ (154,560)
Non cash items:
Deferred tax expense	0	0	770
Depreciation and amortization	173	29	4,144
Non-cash stock-based compensation	34	107	4,965
Gain on sale of bone device business	0	0	(2,298)
In-process research and development	0	0	34,311
Change in other operating items:
Interest, income taxes and other current assets	150	375	1,475
Accounts payable	(145)	156	(883)
Accrued liabilities	(49)	19	(3,004)
Cash flows used in operating activities	(3,951)	(3,367)	(115,080)
INVESTING ACTIVITIES
Expenditures for furniture and equipment, net	0	0	(1,044)
Proceeds from sale of assets	4	172	7,176
Cash paid for assets of AzERx/CBI	0	0	(4,058)
Cash paid for patent rights	0	(378)	(1,028)
Purchases of investments	0	0	(282,538)
Maturities of investments	0	0	340,476
Cash flows provided by (used in) investing activities	4	(206)	58,984
FINANCING ACTIVITIES
Net proceeds from stock option exercises	0	0	4,612
Net proceeds from sale of stock	0	0	3,376
Common stock purchases	0	0	(1,041)
Cash flows provided by financing activities	0	0	6,947
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(3,947)	(3,573)	(49,149)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,205	13,778	55,407
CASH AND CASH EQUIVALENTS, END OF PERIOD	6,258	10,205	6,258
Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions:
Cash paid	0	0	4,058
Lipimetix [Member]
INVESTING ACTIVITIES
Cash paid for assets of AzERx/CBI		(378)
Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions:
Current assets acquired		0
Patent rights acquired		1,045
Liabilities acquired, and accrued acquisition costs		0
Original investment reversal		0
In-process research and development acquired		0
Noncontrolling interest		(667)
Common stock issued for acquisition		0
Cash paid		378
Lipimetix Azerx Cbi [Member]
INVESTING ACTIVITIES
Cash paid for assets of AzERx/CBI			(4,436)
Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions:
Current assets acquired			29
Patent rights acquired			3,187
Liabilities acquired, and accrued acquisition costs			(457)
Original investment reversal			(750)
In-process research and development acquired			34,311
Noncontrolling interest			(667)
Common stock issued for acquisition			(31,217)
Cash paid			$ 4,436